Welcome to our dedicated page for NVTA news (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on NVTA stock.
This page aggregates news and press releases related to Invitae (OTC: NVTA), a medical genetics company that focuses on clinical genetic testing, variant classification, and genomic data research. The news coverage reflects Invitaes role in medical laboratories, health care, and social assistance, as well as its corporate and financial developments.
Company announcements describe Invitae as a provider of genetic information that aims to deliver accurate and actionable results to support medical decision-making. News items include updates on research presented at professional meetings, such as the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting and the American Society of Breast Surgeons Annual Meeting. These stories highlight work on variant reclassification, machine learning models for hereditary cancer and Lynch syndrome genes, and studies of variants of uncertain significance and their impact on clinical management.
Other articles focus on Invitaes technology platforms and data resources, including the Invitae Generation platform and Clinical Variant Modeling, which the company describes as using machine learning and large genomic datasets to improve variant classification. News also covers collaborations with biopharmaceutical partners, such as an agreement with BridgeBio Pharma to use Invitaes rare disease enriched dataset and analytical capabilities for genetics-based drug discovery.
In addition to scientific and product-related updates, the news feed includes major corporate events. These include Invitaes filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey, its court-supervised sale process, and the selection of Labcorp as the winning bidder to acquire substantially all of the companys assets, subject to approvals. Asset transactions involving specific business lines, such as the transfer of certain reproductive health assets to Natera, also appear in coverage.
Investors, clinicians, and others interested in NVTA can use this page to review historical and ongoing developments in Invitaes research activities, technology initiatives, partnerships, restructuring efforts, and asset sales as reported in public news sources.
Invitae (NYSE: NVTA) has partnered with AstraZeneca to utilize its Ciitizen data platform for enhancing research on cholangiocarcinoma, a rare bile duct cancer. Through this collaboration, patient-consented data from the Cholangiocarcinoma Foundation will be leveraged to improve treatment outcomes. The study will track patients on AstraZeneca’s TOPAZ-1 regimen over three years to assess long-term efficacy and tolerability. This initiative aims to bridge gaps in clinical research for rare diseases by incorporating real-world insights into treatment strategies.
Invitae (NYSE: NVTA) announced it will report its third quarter 2022 financial results on November 8, 2022. The company will host a conference call and webcast at 4:30 p.m. Eastern to discuss these results and highlight recent developments. The call can be accessed through registration, providing participants with call details. Invitae aims to integrate genetic information into mainstream medicine, improving healthcare quality and accessibility for a broad audience.
Invitae (NYSE: NVTA) has been appointed to a National Quality Forum (NQF) committee for a three-year term, marking it as the first genetics testing company to join this panel. The committee will focus on quality standards that influence healthcare delivery, with the goal of integrating genetics into mainstream medical practices. This move is anticipated to enhance healthcare quality and potentially improve outcomes for millions, particularly in areas like cancer and cardiovascular disease.
Invitae's recent study published in JAMA Network Open confirms that universal genetic testing significantly improves outcomes for patients with breast cancer. The study involved 952 patients and revealed that genetic testing altered clinical management recommendations for 68% of patients who didn't meet previous testing criteria. With breast cancer affecting over 7 million women globally, the American Society of Breast Surgeons advocates universal testing as the new standard of care, aiming to enhance patient treatment and identify hereditary risks for family members.
Invitae and Praxis Precision Medicines have successfully utilized Invitae's Ciitizen platform to support Praxis' IND application for PRAX-222, a treatment targeting pediatric patients with SCN2A developmental and epileptic encephalopathy. This marks the platform's first use as a source of real-world data in a regulatory filing. The FDA has cleared the IND application for the initial dose cohort of the PRAX-222 EMBRAVE clinical study, emphasizing the importance of innovative data collection in addressing rare diseases where traditional studies are challenging.
Invitae (NYSE: NVTA) has collaborated with clinical experts to advocate for universal germline testing for all cancer patients, as published in the Journal of Clinical Oncology Precision Oncology. The commentary cites a meta-analysis showing that 5-13% of patients with heritable mutations are overlooked due to current testing guidelines. It champions genetic testing to improve treatment options and patient outcomes, aligning with initiatives like Cancer Moonshot 2.0. The need for broader access to genetic testing is emphasized to reduce mortality and disparities in cancer care.
Invitae (NYSE: NVTA) has announced a collaboration with Simons Searchlight to enhance research on rare neurological diseases. This partnership merges Invitae's longitudinal clinical data from its Ciitizen platform with patient-reported outcomes from Simons Searchlight, creating a comprehensive dataset aimed at accelerating research efforts. The initiative seeks to improve understanding and treatment of conditions like STXBP1 and SYNGAP1 disorders. Both organizations emphasize the importance of this collaboration for providing researchers with in-depth knowledge of these disorders.
Invitae (NYSE: NVTA), a leader in medical genetics, will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 8:00 a.m. ET in New York City. The event features a fireside chat where management will discuss the company's initiatives. Investors can access a live audio webcast on the company's website, with a replay available afterward. Invitae aims to make genetic testing mainstream, offering improved quality and lower prices for healthcare worldwide. Visit invitae.com for more information.
Invitae (NYSE: NVTA) reported second-quarter 2022 revenue of $136.6 million, reflecting a 17.5% increase year-over-year. Non-GAAP gross margin improved to 40.1%, up from 36.6% in Q1 2022. However, the company faced a significant net loss of $2.5 billion, largely due to a goodwill writedown of $2.3 billion. Cash and equivalents were $737 million, with a cash burn of $147 million, marking a reduction from previous quarters. Invitae plans to realign operations, extending its cash runway to late 2024, while maintaining a low double-digit revenue growth outlook for 2022.
The National Comprehensive Cancer Network (NCCN) has updated its guidelines to recommend genetic testing for all colorectal cancer (CRC) patients, regardless of age or cancer type. This change addresses previous limitations that often excluded younger patients and those from diverse backgrounds. Recent studies indicate that nearly 1 in 6 CRC patients have inherited mutations affecting treatment, and over 10% had adjusted therapies due to genetic findings. The new guidelines aim to enhance access to testing for underserved populations, potentially impacting millions affected by CRC worldwide.